Key Takeaways
- • OneBio Venture Studio achieved a R100 million ($6 million) first close for its second fund, targeting a final raise of R300 million ($18 million) by mid-2027, positioning itself to deepen capital deployment in Africa's underfunded biotech sector.
- • The Cape Town-based firm operates as a hybrid venture studio and investor, building biotech companies from inception while providing capital—a model adapted from Flagship Pioneering that addresses Africa's constraints in wet-lab infrastructure, regulatory fragmentation, and clinical trial capacity.
- • Portfolio performance demonstrates both attrition and selective success: eight exits and six shutdowns against 16 total investments, with standout winners including LifeQ ($47 million+ in cumulative funding) and CapeBio, while the firm continues backing early-stage ventures such as Altera Biosciences, Biomine, and Bixbio.
- • African venture capital remains heavily concentrated in fintech, e-commerce, and logistics, with biology-led startups facing structural headwinds including extended development timelines, elevated laboratory costs, limited exit pathways, and shallow clinical trial ecosystems—constraints OneBio aims to overcome through hands-on commercialization support.
- • Led by Michael Fichardt, Nick Walker, and Gian-Marco Melfi, OneBio's funding milestone represents a proof-of-concept for deep science venture models in emerging African markets, signaling institutional confidence in biology-led innovation despite high operational complexity.
Summary
OneBio Venture Studio has secured a R100 million ($6 million) first close for its second investment fund, with a stated target of R300 million ($18 million) by mid-2027. The Cape Town-based firm, led by partners Michael Fichardt, Nick Walker, and Gian-Marco Melfi, operates as a hybrid venture studio and early-stage investor focused on life sciences commercialization across Africa. Unlike traditional venture capital structures, OneBio combines capital deployment with hands-on company building, modeling its approach after U.S.-based firms such as Flagship Pioneering, though adapted to address Africa's distinct biotech ecosystem constraints.
The funding milestone reflects a deliberate strategy to address a structural gap in African venture capital allocation. While African VC funding flows predominantly into fintech, e-commerce, and logistics—sectors with shorter commercialization cycles and clearer scalability pathways—biology-led startups face persistent headwinds: extended development timelines, elevated wet-lab infrastructure costs, fragmented regulatory environments, limited clinical trial infrastructure, and shallow exit markets. OneBio's thesis posits that these constraints can be transformed into an investable opportunity if combined with operational support and strategic capital allocation.
OneBio's portfolio history reveals the high-risk nature of deep science venture models in emerging markets. Among 16 total investments, the firm has recorded eight exits and six shutdowns, including WNNR Biotech, Tryad, Gourmet Grubb, MyBiome, and PharmaHealth Technologies. However, the portfolio has produced measurable winners: LifeQ has raised over $47 million across two funding rounds and maintains revenue generation, while CapeBio successfully commercialized pandemic-era diagnostic demand into a sustainable business model. More recently, OneBio co-led a R29 million (approximately $1.6 million) pre-seed round for Altera Biosciences in July 2025 and continues backing ventures including Biomine, Immobazyme, and Bixbio.
The second fund's first close represents not a vindication of past performance but rather a proof-of-concept for African deep science venture models. The capital raise demonstrates institutional confidence in OneBio's ability to build globally competitive biotech companies from African research infrastructure, despite the operational complexity and capital intensity inherent in biology-led ventures. The firm's path to final close by mid-2027 will likely serve as a bellwether for venture studio adoption across Africa's emerging life sciences ecosystem.
The funding milestone reflects a deliberate strategy to address a structural gap in African venture capital allocation. While African VC funding flows predominantly into fintech, e-commerce, and logistics—sectors with shorter commercialization cycles and clearer scalability pathways—biology-led startups face persistent headwinds: extended development timelines, elevated wet-lab infrastructure costs, fragmented regulatory environments, limited clinical trial infrastructure, and shallow exit markets. OneBio's thesis posits that these constraints can be transformed into an investable opportunity if combined with operational support and strategic capital allocation.
OneBio's portfolio history reveals the high-risk nature of deep science venture models in emerging markets. Among 16 total investments, the firm has recorded eight exits and six shutdowns, including WNNR Biotech, Tryad, Gourmet Grubb, MyBiome, and PharmaHealth Technologies. However, the portfolio has produced measurable winners: LifeQ has raised over $47 million across two funding rounds and maintains revenue generation, while CapeBio successfully commercialized pandemic-era diagnostic demand into a sustainable business model. More recently, OneBio co-led a R29 million (approximately $1.6 million) pre-seed round for Altera Biosciences in July 2025 and continues backing ventures including Biomine, Immobazyme, and Bixbio.
The second fund's first close represents not a vindication of past performance but rather a proof-of-concept for African deep science venture models. The capital raise demonstrates institutional confidence in OneBio's ability to build globally competitive biotech companies from African research infrastructure, despite the operational complexity and capital intensity inherent in biology-led ventures. The firm's path to final close by mid-2027 will likely serve as a bellwether for venture studio adoption across Africa's emerging life sciences ecosystem.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.